You searched for side effects - Page 79 of 311 - Medivizor
Navigation Menu

Evaluating sacral neuromodulation with the InterStim system in patients with lower urinary symptoms

Evaluating sacral neuromodulation with the InterStim system in patients with lower urinary symptoms

Posted by on Oct 17, 2020 in Urinary incontinence | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacral neuromodulation (SNM) with the InterStim system in the treatment of lower urinary symptoms such as urinary incontinence (UI) in real-world medical practice. Researchers suggested that this treatment is associated with improved effectiveness and quality of life in these...

Read More

Sacral neuromodulation with the InterStim system is associated with improved outcomes in patients with overactive bladder

Sacral neuromodulation with the InterStim system is associated with improved outcomes in patients with overactive bladder

Posted by on Oct 17, 2020 in Overactive bladder | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacral neuromodulation (SNM) with the InterStim system in the treatment of overactive bladder (OAB) in real-world practice. Researchers suggested that this treatment is associated with improved effectiveness and quality of life in these patients. Some background Overactive bladder...

Read More

Does mirabegron improve the satisfaction of patients with overactive bladder?

Does mirabegron improve the satisfaction of patients with overactive bladder?

Posted by on Oct 17, 2020 in Overactive bladder | 0 comments

In a nutshell This study investigated the effectiveness and impact on patient satisfaction of mirabegron (Myrbetriq) in patients with overactive bladder (OAB). Researchers suggested that this drug improved the treatment satisfaction of patients with OAB. Some background OAB consists of an uncontrollable need to urinate with or without incontinence...

Read More

Investigating the effectiveness of the treatment combination atezolizumab with chemotherapy before surgery for early triple negative breast cancer

Investigating the effectiveness of the treatment combination atezolizumab with chemotherapy before surgery for early triple negative breast cancer

Posted by on Oct 11, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of atezolizumab (Tecentriq) as an addition to chemotherapy before surgery for patients with early-stage triple-negative breast cancer (TNBC). The data showed that the combination is effective in improving treatment response in these patients. Some background...

Read More

Evaluating gemcitabine and vinorelbine as an outpatient treatment of relapsed childhood Hodgkin lymphoma.

Evaluating gemcitabine and vinorelbine as an outpatient treatment of relapsed childhood Hodgkin lymphoma.

Posted by on Oct 11, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study was carried out to assess the safety and effectiveness of a chemotherapy regimen including gemcitabine (Gemzar) and vinorelbine (Navelbine) for relapsed childhood Hodgkin lymphoma (HL). The authors found that this regimen is effective in treating childhood HL in the outpatient setting and there was low...

Read More

Evaluating pembrolizumab consolidation following chemotherapy and radiation for patients with stage III non-small cell lung cancer.

Evaluating pembrolizumab consolidation following chemotherapy and radiation for patients with stage III non-small cell lung cancer.

Posted by on Oct 10, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of pembrolizumab (Keytruda) consolidation therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC) following a course of chemotherapy and radiation therapy. The authors found that pembrolizumab consolidation improved the outcomes of...

Read More

Comparing accelerated partial-breast irradiation and whole-breast irradiation in patients with early breast cancer.

Comparing accelerated partial-breast irradiation and whole-breast irradiation in patients with early breast cancer.

Posted by on Oct 10, 2020 in Breast cancer | 0 comments

In a nutshell This trial was carried out to assess the long-term results of external-beam accelerated partial-breast irradiation (APBI) intensity-modulated radiation therapy (IMRT) compared to whole-breast irradiation (WBI) in early-stage breast cancer (BC). The authors found that the 10-year recurrence of breast tumors was similar between the 2 methods,...

Read More

Evaluating Immunoscore as a prognostic factor in stage 3 colon cancer

Evaluating Immunoscore as a prognostic factor in stage 3 colon cancer

Posted by on Oct 10, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated Immunoscore (IMS) as a prognostic tool in patients with stage 3 colon cancer. Researchers suggested that a high IMS is associated with prolonged survival in these patients. Some background Colorectal cancer is the third most common cancer worldwide. A significant percentage of patients present with high-risk...

Read More

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Posted by on Oct 10, 2020 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to examine the effectiveness and safety of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone (Decadron) in relapsed or refractory (unresponsive) multiple myeloma (MM). The authors found that there was an improved survival in these patients in the long-term. Some...

Read More